Jennifer E Amengual
Columbia University in the City of New York
H-index: 22
North America-United States
Top articles of Jennifer E Amengual
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
Leukemia & Lymphoma
2024/3/22
Salvia Jain
H-Index: 14
Jennifer E Amengual
H-Index: 18
JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24. 1 Amplified Lymphoma, Priming for Enhanced Antigenicity
Blood
2023/11/28
Yun Kyoung Ryu
H-Index: 10
Jennifer E Amengual
H-Index: 18
First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL
Blood
2023/11/28
Yun Kyoung Ryu
H-Index: 10
Jennifer E Amengual
H-Index: 18
Outcomes in Minorities with PTCL By Clinical Trial Enrollment
Blood
2023/11/28
Jennifer E Amengual
H-Index: 18
Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin …
Blood
2023/11/28
Jennifer E Amengual
H-Index: 18
Hypereosinophilic syndrome with leptomeningeal involvement: a not-so-classical case report of classical Hodgkin Lymphoma
Leukemia & Lymphoma
2023/11/10
The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder
Blood
2023/11/2
How I treat posttransplant lymphoproliferative disorder
2023/10/26
Jennifer E Amengual
H-Index: 18
ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma
Nature Communications
2023/7/17
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL
Hematological Oncology
2023/6
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL
Hematological Oncology
2023/6
ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA
Hematological Oncology
2023/6
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS
Hematological Oncology
2023/6
Combination therapy of lymphoma
2023/6/1
Histone acetyltransferase activators and compositions and uses thereof
2023/6/1
Queen's gambit: response-adapted win in CAYA with cHL
Blood
2023/4/27
Jennifer E Amengual
H-Index: 18
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Blood Advances
2023/12/26
Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL
Blood
2023/11/28
Zhengming Chen
H-Index: 25
Evelyn Orlando
H-Index: 5
Peter Martin
H-Index: 11
John P Leonard
H-Index: 7
Jennifer E Amengual
H-Index: 18
